Literature DB >> 17936915

Multifaceted aspects of inflammation in multiple sclerosis: the role of microglia.

Luca Muzio1, Gianvito Martino, Roberto Furlan.   

Abstract

The very simplistic view that inflammation in multiple sclerosis (MS) is tout court detrimental has to be profoundly reconsidered. Experimental evidence strongly supports the concept that inflammation in MS is aimed not only at destroying and phagocytosing damaged (infected?) cells (detrimental phase) but also at promoting tissue regeneration or tissue repair via scar formation (resolution or protective phase). Microglia seem to play a crucial role in the different inflammatory phases in MS because they move through multiple functional levels (quantum jumps) either to remove the "danger" signal or to restore the integrity of the central nervous system. The understanding of the molecular signature of any of the quantum microglial states could be useful to better define the cellular and molecular mechanisms underling the different phases of inflammation in MS. This could contribute not only to the design of better therapeutic drugs, but also to the comprehension of the shortcomings of currently used anti-inflammatory drugs.

Entities:  

Mesh:

Year:  2007        PMID: 17936915     DOI: 10.1016/j.jneuroim.2007.09.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

1.  Intravenous administration of human embryonic stem cell-derived neural precursor cells attenuates cuprizone-induced central nervous system (CNS) demyelination.

Authors:  S J Crocker; R Bajpai; C S Moore; R F Frausto; G D Brown; R R Pagarigan; J L Whitton; A V Terskikh
Journal:  Neuropathol Appl Neurobiol       Date:  2011-10       Impact factor: 8.090

Review 2.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  Inhibition of TLR ligand- and interferon gamma-induced murine microglial activation by Panax notoginseng.

Authors:  Celine A Beamer; David M Shepherd
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-21       Impact factor: 4.147

Review 4.  The mechanism of action of interferon-β in relapsing multiple sclerosis.

Authors:  Bernd C Kieseier
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

5.  HMGB1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia.

Authors:  Nabanita Das; Varun Dewan; Peter M Grace; Robin J Gunn; Ryo Tamura; Netanel Tzarum; Linda R Watkins; Ian A Wilson; Hang Yin
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

6.  Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.

Authors:  Antonietta Gentile; Silvia Rossi; Valeria Studer; Caterina Motta; Valentina De Chiara; Alessandra Musella; Helena Sepman; Diego Fresegna; Gabriele Musumeci; Giorgio Grasselli; Nabila Haji; Sagit Weiss; Liat Hayardeny; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-31       Impact factor: 4.147

7.  Microglia Are Critical in Host Defense against Prion Disease.

Authors:  James A Carroll; Brent Race; Katie Williams; James Striebel; Bruce Chesebro
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

8.  Matrix metalloproteinase-12 deficiency worsens relapsing-remitting experimental autoimmune encephalomyelitis in association with cytokine and chemokine dysregulation.

Authors:  Angelika Goncalves DaSilva; V Wee Yong
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

9.  Peripheral formalin injection induces unique spinal cord microglial phenotypic changes.

Authors:  Kai-Yuan Fu; Yong-Hui Tan; Backil Sung; Jianren Mao
Journal:  Neurosci Lett       Date:  2008-11-11       Impact factor: 3.046

10.  The contributing role of CD14 in toll-like receptor 4 dependent neuropathic pain.

Authors:  L Cao; F Y Tanga; J A Deleo
Journal:  Neuroscience       Date:  2008-10-07       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.